“Our commitment and employing a clinical development strategy for novel ingredients such as PS128™ is really leading the way to create evidence-based functional food and supplement products in the marketplace overall,” said Frankie Cheng, CEO of Bened Biomedical Co. Ltd. “We want our customers in the United States to know that we are fully dedicated to investing into our products and processes from beginning to end, and ensuring we are a reliable supplier in terms of safety and efficacy as well as all of the compliance requirements from the FDA.”
The patented strain of Lactobacillus Plantarum PS128™ was developed from extensive research for the improvement of mental, neurological, and gastrointestinal health. The Self-affirmed GRAS consensus was attained after a formal and stringent review by an independent expert panel.
“REJIMUS was honoured to earn this opportunity to work with Bened Biomedical in bringing such a novel patented ingredient to the U.S.,” said Brandon Griffin, CEO of REJIMUS, INC. “In addition to the PS128™ introduction to the U.S. market, the development and implementation of Bened’s supply chain and quality systems to better align with that of their U.S. customers’ anticipated needs was a tremendous undertaking in these unprecedented times. Many of our clients here in the U.S. have been negatively impacted by their international suppliers due to the pandemic, so guiding Bened Biomedical in the preparation from an operational and compliance standpoint to rapidly attract more customers was paramount.”
